PREDICTORS OF G-CSF PROPHYLAXIS IN THE FIRST CYCLE OF CHEMOTHERAPY FOR FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Lugtenburg, P. [1 ]
Asubonteng, J. [2 ]
DeCosta, L. [3 ]
Szabo, Z. [4 ]
Page, J. H. [5 ]
Wetten, S. [3 ]
机构：
[1] Erasmus Mc Canc Inst, Rotterdam, Netherlands
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Amgen Ltd, London, England
[4] Amgen Inc, Zug, Switzerland
[5] Amgen Inc, Thousand Oaks, CA USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P583
引用
收藏
页码：196 / 196
页数：1
相关论文
共 50 条
  • [1] Predictors of G-CSF Prophylaxis in the First Cycle of Chemotherapy in Non-Hodgkin's Lymphoma Patients
    Asubonteng, Julius
    Wetten, Sally
    Lugtenburg, Pieternella J.
    DeCosta, Lucy
    Szabo, Zsolt
    Page, John H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 60 - 61
  • [2] RISK OF FEBRILE NEUTROPENIA AND USE OF G-CSF PRIMARY PROPHYLAXIS IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING R-CHOP-21
    Haioun, C.
    Jaeger, U.
    Lugtenburg, P.
    Pettengell, R.
    Principe, F.
    Rossi, F.
    Salar, A.
    Schwenkglenks, M.
    Verhoef, G.
    Edmundson, S.
    Bacon, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 105 - 105
  • [3] G-CSF prophylaxis of febrile neutropenia and infections after chemotherapy
    Link, H.
    ONKOLOGE, 2014, 20 (03): : 268 - 270
  • [4] Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study)
    Wolff, Thomas
    Schulz, Holger
    Losem, Christoph
    Reichert, Dietmar
    Hurtz, Hans-Juergen
    Sandner, Reiner
    Harde, Johanna
    Grebhardt, Sina
    Potthoff, Karin
    Mueller, Udo
    Fietz, Thomas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (02) : 174 - 181
  • [5] The effect of G-CSF after chemotherapy with CHOP in patients with non-Hodgkin's lymphoma and HIV infection
    Navarro, JT
    Ribera, JM
    GomezEspuch, J
    Feliu, E
    MEDICINA CLINICA, 1996, 107 (03): : 118 - 119
  • [6] Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin's Lymphoma
    Engert, Andreas
    del Giglio, Auro
    Bias, Peter
    Lubenau, Heinz
    Gatzemeier, Ulrich
    Heigener, David
    ONKOLOGIE, 2009, 32 (10): : 599 - 604
  • [7] ECONOMIC MODEL OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) IN PRIMARY (PP) AND SECONDARY PROPHYLAXIS (SP) OF FEBRILE NEUTROPENIA (FN) IN NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS UNDERGOING CHEMOTHERAPY IN FRANCE
    Perrier, L.
    Sebban, C.
    Leon, N.
    Maurel, F.
    Cohen-Nizard, S.
    De Liege, F.
    VALUE IN HEALTH, 2011, 14 (07) : A450 - A450
  • [8] First line-intensive chemotherapy (EPOCH-G) supported with G-CSF for Non-Hodgkin Lymphoma
    Ito, Y
    Kato, C
    Horikoshi, N
    Nakane, M
    Nakano, Y
    Osawa, H
    Mihara, H
    Irie, T
    Takahashi, S
    Aiba, K
    BLOOD, 1995, 86 (10) : 201 - 201
  • [9] Integration of G-CSF in the prophylaxis and treatment of febrile neutropenia
    Siegmund, R
    Illiger, HJ
    MEDIZINISCHE KLINIK, 1996, 91 (02) : 82 - 88
  • [10] Influence of medicare claim-paying agents' reimbursement policy on G-CSF choice during first cycle of chemotherapy for non-Hodgkin's lymphoma patients
    Pan, X.
    Brooks, J. M.
    Wright, K. B.
    Voelker, M. D.
    VALUE IN HEALTH, 2008, 11 (03) : A12 - A12
12345